Axela Bio, a CRO specializing in discovery biology and Translational Sciences.
Welcome to Our New Gold Standard of Proteomics, NULISA
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Highly Sensitive & Reproducible
Ultra-high sensitivity (attomolar to femtomolar) to detect low abundant targets. Median CVs <10%
12 logs Dynamic Range
Absolute Quantitation of a broad spectrum of protein abundances in a single assay
High multiplexing capability
Enables simultaneous measurement of hundreds to thousands of proteins
About our NULISA proteomics assay
Reliable, fully automated workflow
- Fully validated and quality-controlled assays
- Flexible assay design options: pre-made panels (92 or 45 protein assays) or customizable panels (up to 21 proteins)
- Highly robust and reproducible assay suitable for screening on both small and large scales
- State-of-the-art platforms utilized, with readout performed using the Fluidigm® BioMark™ HD system
- Quick turnaround time, providing concise and quantitative data within 2-4 weeks
- Comprehensive study report delivered in a high-quality publication-style format
How It Works
The NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation. By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next-Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing.
Automated, hands-free workflows reduce inter-operator and inter-site variability while liberating valuable scientist and technician time from the bench to tackle more challenging initiatives. The ARGO™ HT System offers ease of integration into existing workflows, its purpose-built design will become a cornerstone of biomarker research, providing rapid, reliable results with minimal intervention.
NULISA: The New Standard in Precision Proteomics
The NULISA™ (NUcleic acid Linked Immuno-Sandwich Assay) is the future of protein biomarker discovery and analysis. This next-generation proteomics technology is the first to deliver on all four liquid biopsy protein profiling needs with best-in-class capabilities:
- Attomolar (low fg/ml) sensitivity and low cross-reactivity
- ~10-log dynamic range covering low- and high-abundance targets
- Curated panels of hundreds of disease-relevant markers with NGS-capable sample-mixing in one well
- Purpose-built, sample-to-sequence automated system with excellent intra- and inter-plate precision
